WO2009023160A8 - Novel inhibitors of bacterial sortase enzymes and methods of using the same - Google Patents

Novel inhibitors of bacterial sortase enzymes and methods of using the same Download PDF

Info

Publication number
WO2009023160A8
WO2009023160A8 PCT/US2008/009577 US2008009577W WO2009023160A8 WO 2009023160 A8 WO2009023160 A8 WO 2009023160A8 US 2008009577 W US2008009577 W US 2008009577W WO 2009023160 A8 WO2009023160 A8 WO 2009023160A8
Authority
WO
WIPO (PCT)
Prior art keywords
methods
same
novel inhibitors
bacterial
sortase enzymes
Prior art date
Application number
PCT/US2008/009577
Other languages
French (fr)
Other versions
WO2009023160A2 (en
WO2009023160A3 (en
Inventor
Sadanandan E. Velu
Sthanam V.L. Narayana
Aaron L. Lucius
Original Assignee
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Uab Research Foundation filed Critical The Uab Research Foundation
Publication of WO2009023160A2 publication Critical patent/WO2009023160A2/en
Publication of WO2009023160A3 publication Critical patent/WO2009023160A3/en
Publication of WO2009023160A8 publication Critical patent/WO2009023160A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present disclosure describes novel small-molecule inhibitors of bacterial sortases. The identified inhibitors may be used in the methods of treatment and prevention described in the present disclosure.
PCT/US2008/009577 2007-08-11 2008-08-11 Novel inhibitors of bacterial sortase enzymes and methods of using the same WO2009023160A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95535307P 2007-08-11 2007-08-11
US60/955,353 2007-08-11

Publications (3)

Publication Number Publication Date
WO2009023160A2 WO2009023160A2 (en) 2009-02-19
WO2009023160A3 WO2009023160A3 (en) 2009-05-07
WO2009023160A8 true WO2009023160A8 (en) 2011-11-24

Family

ID=40351355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/009577 WO2009023160A2 (en) 2007-08-11 2008-08-11 Novel inhibitors of bacterial sortase enzymes and methods of using the same

Country Status (1)

Country Link
WO (1) WO2009023160A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011084882A2 (en) * 2010-01-05 2011-07-14 Contrafect Corporation Methods and compositions for enhanced immunological therapy and targeting of gram-positive bacteria
GB201003089D0 (en) * 2010-02-24 2010-04-14 London School Hygiene & Tropical Medicine Clostridium gene
EP2875815A1 (en) * 2013-11-21 2015-05-27 Latvian Biomedical Research and Study Centre N'-(2-(3-oxobenzo[d]isothiazol-2(3h)-yl)acetyl)adamantane-1-carbohydrazide as a novel inhibitor for staphylococcus aureus sortase a
EP2875816A1 (en) * 2013-11-21 2015-05-27 Latvian Biomedical Research and Study Centre N-(3-hydroxy-5,7-dimethyladamantan-1-yl)-2-(3-oxobenzo[d]isothiazol-2(3h)-yl)acetamide as a novel inhibitor for staphylococcus aureus sortase a
CN107904279A (en) * 2017-11-03 2018-04-13 中国农业科学院北京畜牧兽医研究所 A kind of screening technique of staphylococcus aureus inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003049702A2 (en) * 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors

Also Published As

Publication number Publication date
WO2009023160A2 (en) 2009-02-19
WO2009023160A3 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
WO2007136815A3 (en) Tagged microorganisms and methods of tagging
WO2006105304A8 (en) Phenyl and pyridyl lta4h modulators
WO2007025247A3 (en) Transglutaminase inhibitors and methods of use thereof
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
WO2007025169A3 (en) Hif inhibitors
WO2007097940A3 (en) Reca inhibitors with antibiotic activity, compositions and methods of use
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2006020767A3 (en) Thiazole based inhibitors of atp-utilizing enzymes
WO2008098104A8 (en) Inhibitors of akt activity
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2007050795A3 (en) Transglutaminase inhibitors and methods of use thereof
IL176478A0 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the faah enzyme
WO2006083924A8 (en) 1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
IL177422A0 (en) Derivatives of alkylpiperazine-and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
IL177534A0 (en) Derivatives of piperidinylalkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors
EP2086999A4 (en) Inhibitors for disrupting the interaction of ubiquitination related enzymes and uses thereof
WO2009082445A3 (en) Novel devices for the detection of the presence and/or activity of proteases in biological samples
WO2009023160A8 (en) Novel inhibitors of bacterial sortase enzymes and methods of using the same
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2006084153A3 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
IL181819A0 (en) Enzyme inhibitors and uses thereof
WO2004087066A3 (en) Hif-1 inhibitors
RS54140B1 (en) Use of 24-norudca
WO2007014772A3 (en) Direct and indirect effector cell protease receptor-1 (epr-1) inhibitors as antiplatelet agents
WO2007117419A8 (en) Methods and compositions relating to post-prolyl cleaving enzyme inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08795186

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08795186

Country of ref document: EP

Kind code of ref document: A2